NBTY Expands Into Mass Market With Zila Acquisition
This article was originally published in The Tan Sheet
Executive Summary
NBTY is looking to use Ester-C brand recognition and loyalty to gain traction in the mass retail market
You may also be interested in...
NBTY’s Ester-C Plans Under Wraps But Shining Through; Firms Strategize
NOW Foods is developing a "replacement Ester-C product" with the goal of selling it as a branded ingredient to other firms, National Sales Manager Dan Richard told "The Tan Sheet.
J&J, Pfizer Satisfy FTC Conditions To Clear Deal; EC Signs Off
Johnson & Johnson and Pfizer's divestiture of the Zantac, Cortizone, Unisom and Balmex brands satisfies the Federal Trade Commission's anticompetitive complaint about J&J's acquisition of Pfizer's consumer healthcare business
Zila divertiture approved
Zila receives shareholder approval to divest wholly-owned subsidiary Zila Nutraceuticals to NBTY, the Phoenix-based firm announces Sept. 28. The company expects the divestiture to be completed Oct. 2 for $37.5 mil. in a total cash transaction with up to an additional $3 mil. to be paid through an "earn-out formula dependent upon the future performance of the business." NBTY in August announced the proposed acquisition of the nutraceutical division, which includes the Ester-C and Ester-E branded ingredients (1"The Tan Sheet," Aug. 21, 2006, p. 5)...